.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,309,127

« Back to Dashboard

Claims for Patent: 8,309,127

Title:Stable compositions of famotidine and ibuprofen
Abstract: Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface area surrounded by a layer of ibuprofen. In some embodiments, the ibuprofen is in direct physical contact with the famotidine.
Inventor(s): Xu; Jerry (Hunt Valley, MD), Tidmarsh; George F. (Portola Valley, CA)
Assignee: Horizon Pharma USA, Inc. (Deerfield, IL)
Application Number:13/403,923
Patent Claims: 1. A pharmaceutical composition comprising: a first layer comprising from 750 mg to 850 mg ibuprofen as an active pharmaceutical ingredient and a second layer comprising from 24 mg to 28 mg famotidine as an active pharmaceutical ingredient, wherein the active pharmaceutical ingredients are in direct contact, wherein the pharmaceutical composition is in the form of a tablet, provided that if the pharmaceutical composition is a table-in-tablet formulation, then the first layer completely surrounds the second layer, wherein the pharmaceutical composition is formulated for immediate release, and wherein none of the composition, the first layer, the second layer, the famotidine, or the ibuprofen is enterically coated or formulated for sustained release, wherein the pharmaceutical composition is formulated so that release of the ibuprofen active pharmaceutical ingredient and the famotidine active pharmaceutical ingredient begins to occur at about the same time, wherein the famotidine is not present as barrier coated famotidine multiparticulates dispersed in an ibuprofen matrix, wherein the direct contact between the famotidine active pharmaceutical ingredient and the ibuprofen active pharmaceutical ingredient is limited, and wherein at least 90% of the amount of ibuprofen initially present and at least 90% of the amount of famotidine initially present remains after the composition is stored at 40.degree. C. and 75% relative humidity for a period of one month.

2. The pharmaceutical composition of claim 1, wherein at least 95% of the amount of ibuprofen initially present remains after the composition is stored at 40.degree. C. and 75% relative humidity for a period of one month.

3. The pharmaceutical composition of claim 1, wherein at least 90% of the amount of ibuprofen initially present remains after the composition is stored at 40.degree. C. and 75% relative humidity for a period of three months.

4. The pharmaceutical composition of claim 1, wherein at least 95% of the amount of ibuprofen initially present remains after the composition is stored at 40.degree. C. and 75% relative humidity for a period of three months.

5. The pharmaceutical composition of claim 1, wherein at least 90% of the amount of ibuprofen initially present remains after the composition is stored at 40.degree. C. and 75% relative humidity for a period of six months.

6. The pharmaceutical composition of claim 1, wherein at least 95% of the amount of ibuprofen initially present remains after the composition is stored at 40.degree. C. and 75% relative humidity for a period of six months.

7. The pharmaceutical composition of claim 1, wherein at least 95% of the amount of famotidine initially present remains after the composition is stored at 40.degree. C. and 75% relative humidity for a period of one month.

8. The pharmaceutical composition of claim 1, wherein at least 90% of the amount of famotidine initially present remains after the composition is stored at 40.degree. C. and 75% relative humidity for a period of three months.

9. The pharmaceutical composition of claim 1, wherein at least 95% of the amount of famotidine initially present remains after the composition is stored at 40.degree. C. and 75% relative humidity for a period of three months.

10. The pharmaceutical composition of claim 1, wherein at least 90% of the amount of famotidine initially present remains after the composition is stored at 40.degree. C. and 75% relative humidity for a period of six months.

11. The pharmaceutical composition of claim 1, wherein at least 95% of the amount of famotidine initially present remains after the composition is stored at 40.degree. C. and 75% relative humidity for a period of six months.

12. The pharmaceutical composition of claim 1, wherein the composition is a tablet-in-tablet formulation.

13. The pharmaceutical composition of claim 1, wherein the composition is a bilayer tablet.

14. A pharmaceutical composition comprising: a first layer comprising from 750 mg to 850 mg ibuprofen as an active pharmaceutical ingredient and a second layer comprising from 24 mg to 28 mg famotidine as an active pharmaceutical ingredient, wherein the pharmaceutical composition is in the form of a tablet, provided that if the pharmaceutical composition is a table-in-tablet formulation, then the first layer completely surrounds the second layer, wherein the pharmaceutical composition is formulated for immediate release, and wherein none of the composition, the first layer, the second layer, the famotidine, or the ibuprofen is enterically coated or formulated for sustained release, wherein the pharmaceutical composition is formulated so that release of the ibuprofen active pharmaceutical ingredient and the famotidine active pharmaceutical ingredient begins to occur at about the same time, wherein the famotidine is not present as barrier coated famotidine multiparticulates dispersed in an ibuprofen matrix, wherein the famotidine active pharmaceutical ingredient and the ibuprofen active pharmaceutical ingredient have a surface area of direct physical contact that does not exceed 130 mm.sup.2, and wherein at least 90% of the amount of ibuprofen initially present and at least 90% of the amount of famotidine initially present remains after the composition is stored at room temperature for a period of three months.

15. The pharmaceutical composition of claim 14, wherein at least 95% of the amount of ibuprofen initially present remains after the composition is stored at room temperature for a period of three months.

16. The pharmaceutical composition of claim 14, wherein at least 90% of the amount of ibuprofen initially present remains after the composition is stored at room temperature for a period of six months.

17. The pharmaceutical composition of claim 14, wherein at least 95% of the amount of ibuprofen initially present remains after the composition is stored at room temperature for a period of six months.

18. The pharmaceutical composition of claim 14, wherein at least 90% of the amount of ibuprofen initially present remains after the composition is stored at room temperature for a period of nine months.

19. The pharmaceutical composition of claim 14, wherein at least 90% of the amount of ibuprofen initially present remains after the composition is stored at room temperature for a period of 12 months.

20. The pharmaceutical composition of claim 14, wherein at least 90% of the amount of ibuprofen initially present remains after the composition is stored at room temperature for a period of 24 months.

21. The pharmaceutical composition of claim 14, wherein at least 90% of the amount of ibuprofen initially present remains after the composition is stored at room temperature for a period of 36 months.

22. The pharmaceutical composition of claim 14, wherein at least 95% of the amount of famotidine initially present remains after the composition is stored at room temperature for a period of three months.

23. The pharmaceutical composition of claim 14, wherein at least 90% of the amount of famotidine initially present remains after the composition is stored at room temperature for a period of six months.

24. The pharmaceutical composition of claim 14, wherein at least 95% of the amount of famotidine initially present remains after the composition is stored at room temperature for a period of six months.

25. The pharmaceutical composition of claim 14, wherein at least 90% of the amount of famotidine initially present remains after the composition is stored at room temperature for a period of nine months.

26. The pharmaceutical composition of claim 14, wherein at least 90% of the amount of famotidine initially present remains after the composition is stored at room temperature for a period of 12 months.

27. The pharmaceutical composition of claim 14, wherein at least 90% of the amount of famotidine initially present remains after the composition is stored at room temperature for a period of 24 months.

28. The pharmaceutical composition of claim 14, wherein at least 90% of the amount of famotidine initially present remains after the composition is stored at room temperature for a period of 36 months.

29. The pharmaceutical composition of claim 14, wherein the composition is a tablet-in-tablet formulation.

30. The pharmaceutical composition of claim 14, wherein the composition is a bilayer tablet.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc